Arog Pharmaceuticals

General Information


We are a late-stage biopharmaceutical company dedicated to improving the lives of cancer patients by developing crenolanib in indications with high unmet need. Crenolanib is an orally administered, highly potent and selective, mutation-resistant pan-FLT3 inhibitor. To date, crenolanib has been evaluated in over 400 patients across 19 completed or ongoing clinical trials. In Phase I/II clinical trials of crenolanib combined with intensive chemotherapy in patients with relapsed or refractory and newly diagnosed FLT3-mutated acute myeloid leukemia, or AML, composite complete remission has been observed in 68% and 85% of patients, respectively, as evidenced by the reduction in leukemic blasts to less than or equal to 5% in the bone marrow.

Employees: 20
Founded: 2010
Contact Information
Address 5420 LBJ Freeway, Suite 410 Dallas, TX, 75240, US
Phone Number (214) 593-0500
Web Address
View Prospectus: Arog Pharmaceuticals
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-13.2 mil (last 12 months)
IPO Profile
Symbol AROG
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $74.8 mil
Manager / Joint Managers Citigroup/ RBC Capital Market/ Nomura
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change